Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Public Health Minister Nicola Blackwood this week announced that the UK has a specialist team of health experts ready to be deployed to tackle outbreaks of deadly disease anywhere in the world within 48 hours.

Medics in protective hazzard suits

The UK Public Health Rapid Support Team (PHRST) will be on call to respond to urgent requests from countries around the world and fly in to help tackle disease outbreaks at source. The University of Oxford epidemic diseases research group, led by Professor Peter Horby, is providing the clinical research capabilities of the PHRST.

Professor Horby said: “Our epidemic diseases research group has unparalleled experience of conducting clinical research on major emerging and epidemic infectious diseases, from SARS and bird flu to Ebola. We are delighted to be part of this new team because it integrates public health and research, and it recognises the critical role of science in delivering rapid and reliable evidence to improve the care of patients and the control of outbreaks."

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Research programme tackling COVID-19 variants of concern receives funding boost

A gift from the Red Avenue Foundation will enable the expansion of a major research programme aimed at rapidly identifying and interrogating emerging COVID-19 variants.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.